Cash Flow Statement (Annual)
LNT / Alliant Energy Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||129,700||306,300||321,900||335,700||376,200||393,300||388,400||381,700||467,500|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Depreciation And Amortization||273,600||287,300||323,800||332,400||370,900||388,100||401,300||411,600||461,800|
|Depreciation And Amortization Cash Flow||-||-||-||-||-||-||-||-||-|
|Adjustment Depreciation And Amortization Including Discontinued Operations||275,600||292,300||323,800||332,900||370,900||388,100||401,300||411,600||461,800|
|Other Operating Activities Cash Flow Statement||-||-||-||-||-||54,200||12,400||-4,800||21,700|
|Other Amortization Of Deferred Charges||42,100||51,800||56,300||55,000||40,200||54,200||12,400||-||-|
|Deferred Income Taxes And Tax Credits||94,300||216,600||10,200||143,300||108,300||55,200||114,200||84,600||139,600|
|Income Loss From Equity Method Investments||36,600||38,100||39,300||41,300||43,700||40,400||33,800||39,600||44,800|
|Equity Method Investment Dividends Or Distributions||29,900||32,200||32,300||34,200||35,400||36,400||30,600||28,300||38,100|
|Other Noncash Income Expense||5,700||4,700||5,200||2,600||3,700||-2,000||-15,700||-800||-6,700|
|Increase Decrease In Allowance For Equity Funds Used During Construction||28,200||11,200||7,600||14,100||20,300||23,100||24,400||42,300||33,600|
|Impairment Of Long Lived Assets Held For Use||-||-||-||-||-||0||0||86,400||0|
|Non Cash Valuation Charges||20,400||38,000||25,500||3,300||-||-||-||-||-|
|Increase Decrease In Operating Capital|
|Increase Decrease In Accounts Receivable||-73,500||-16,300||54,300||-61,300||49,200||-48,700||-36,800||121,400||-29,600|
|Increase Decrease In Other Receivables||25,000||-65,000||-75,000||10,000||101,000||7,000||17,000||-16,000||9,000|
|Increase Decrease In Income Taxes Receivable||102,300||-130,400||-300||-20,900||-||-||-||-||-|
|Increase Decrease In Fossil Fuel Inventories||28,500||-17,400||-22,500||-||-||-||-||-||-|
|Gas Stored Underground||-||-||-||-||-||-||-||-||-|
|Increase Decrease In Other Regulatory Assets||163,900||20,800||413,100||178,100||-140,500||439,800||104,500||3,600||130,800|
|Increase Decrease In Accounts Payable||-||-||-||-||-||-||-||-||-|
|Increase Decrease In Regulatory Liabilities||136,700||8,400||168,300||16,400||-90,800||10,800||-67,800||-63,000||-83,800|
|Increase Decrease In Income And Other Taxes Payable Noncurrent||60,700||-66,600||-5,100||-2,900||-||-||-||-||-|
|Increase Decrease In Accrued Taxes Payable||25,800||-32,400||2,000||-||-||-||-||-||-|
|Increase Decrease In Pension And Postretirement Obligations||-190,000||-20,100||8,900||51,300||-157,400||215,100||30,100||38,100||-|
|Increase Decrease In Derivative Liabilities||16,300||-52,000||10,700||-37,600||-||-||-||-||-|
|Increase Decrease In Deferred Income Taxes||-118,900||-28,900||-148,500||-69,700||-101,900||-138,400||-94,600||-102,400||-81,700|
|Increase Decrease In Other Operating Capital Net||-10,400||-12,200||-21,100||14,200||-23,700||-59,700||5,400||15,600||-38,700|
|Net Cash Provided By Used In Operating Activities||657,100||984,900||702,700||841,100||731,000||891,600||871,200||859,600||983,400|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Productive Assets Business Line1||1,149,600||0||608,100||403,500||0||0||-||-||-|
|Payments To Acquire Productive Assets Business Line2||53,000||33,600||65,300||132,600||66,700||63,900||70,700||54,100||185,100|
|Payments To Acquire Productive Assets Other||-||833,300||608,100||622,000||731,600||838,900||963,600||1,142,700||1,281,800|
|Proceeds From Sale Of Productive Assets||-||-||-||-||0||0||139,900||0||0|
|Payments For Proceeds From Other Investing Activities||16,600||16,700||4,600||19,900||18,800||14,900||24,800||-10,300||29,400|
|Proceeds From Sale Of Wind Project Assets To Affiliate||-||-||-||-||-||-||-||-||-|
|Net Cash Provided By Used In Investing Activities||-1,148,900||-866,500||-652,100||-1,155,500||-754,700||-917,700||-919,200||-1,186,500||-1,496,300|
|Proceeds From Cash Grant||-||-||-||0||62,400||0||0||-||-|
|Advances For Customer Energy Efficiency Projects||31,000||17,100||5,100||400||-||-||-||-||-|
|Collections Of Advances For Customer Energy Efficiency Projects||63,600||34,200||31,000||22,900||-||-||-||-||-|
|Net Cash Provided By Used In Financing Activities|
|Payments Of Dividends Common Stock||165,500||174,600||188,100||199,300||208,300||225,800||247,300||266,500||288,300|
|Proceeds From Issuance Of Common Stock||-||-||-||-||0||0||151,200||26,600||149,600|
|Payments Of Dividends Preferred Stock And Preference Stock||18,700||18,700||16,800||15,900||11,400||10,200||-||-||-|
|Proceeds From Contributions From Parent||-||-||-||-||-||-||-||-||-|
|Repayment Of Capital To Parent||-||-||-||-||-||-||-||-||-|
|Payments Of Capital Distribution||-||-||-||-||-||-||-||-||-|
|Proceeds From Repayments Of Short Term Debt||103,900||-142,600||55,400||164,700||11,900||-138,100||18,500||84,300||171,100|
|Proceeds From Repayments Of Bank Overdrafts||-||-||-||-||-||-||-||-||-|
|Payments For Repurchase Of Redeemable Preferred Stock||-||0||40,000||0||211,000||0||0||-||-|
|Proceeds From Payments For Other Financing Activities||-21,800||9,300||-8,100||-8,900||-28,800||-7,100||6,800||-1,700||-45,200|
|Proceeds From Issuance Of Redeemable Preferred Stock||-||-||-||0||200,000||0||0||-||-|
|Proceeds From Issuance Of Long Term Debt||800,200||500,000||400||385,000||250,000||812,900||250,700||800,000||550,000|
|Net Cash Provided By Used In Financing Activities||320,200||-134,400||-198,500||324,200||12,300||73,200||-3,100||329,300||532,600|
|Repayments Of Long Term Debt||377,900||307,800||1,300||1,400||1,500||358,500||183,000||313,400||4,600|
|Cash And Cash Equivalents Period Increase Decrease||-171,600||-16,000||-147,900||9,800||-11,400||47,100||-51,100||2,400||19,700|
|Cash And Cash Equivalents At Carrying Value||-||-||11,400||21,200||-||56,900||5,800||8,200||27,900|
|Supplemental Cash Flow Information|
|Interest Paid Net||142,400||165,500||157,600||155,200||171,700||180,800||184,800||192,400||212,600|
|Income Taxes Paid Net||-140,700||-116,200||-10,800||-20,300||-9,600||-5,300||0||9,800||11,300|
|Cash Flow Noncash Investing And Financing Activities Disclosure|
|Capital Expenditures Incurred But Not Yet Paid||66,700||75,000||49,700||105,300||103,800||160,300||148,300||154,400||196,500|
|Transfer Of Investments||-||-||-||-||-||-||-||-||-|
Peers - Electric and Other Services Combined (4931)
ALE / ALLETE, Inc.
AVA / Avista Corp.
CMS / CMS Energy Corp.
CMSA / CMS Energy Corporation
ED / Consolidated Edison, Inc.
EXC / Exelon Corp.
EXCU / Exelon Corp., 6.50% Equity Units
GNE / Genie Energy Ltd.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET